APEX1 and breast carcinoma: With respect to APEX1 Asp148Glu polymorphism, a meta-analysis by Wu et al. [15] found that the APEX1 Asp148Glu polymorphism may not contribute to breast cancer risk, however, they failed to include all eligible studies in the meta-analysis [16,17], which make their conclusions questionable.